Over the past two decades, engineered cell therapies have generated remarkable outcomes in patient populations that previously had few or no remaining treatment options. What once seemed like a highly experimental concept has evolved into a clinically validated therapeutic approach, and today cell therapy remains one of the most closely watched areas of modern biotechnology. The ex-vivo isolation and specific reprogramming of T-cells in CRTH is a real breakthrough, but remains cumbersome, expensive, and invasive. Why is it necessary to kidnap and send T-Cells to an isolation unit in order to get them to follow the physician's script?

With the recently announced success of Merck and Moderna's melanoma vaccination based on patient-specific tumor neoantigens, we imay be reaching a Moore's Law point in the evolution of engineered cell therapy. This advance is noteworthy in that targeted lipid nanoparticles (LNPs) were used to reprogram the T-cells in vivo, eliminating the cost and difficulties of ex vivo reprogramming.

"One thing I've learned after more than forty years in biotechnology is that every important technology eventually reaches a critical turning point," Maxey says. "The first challenge is proving it works. But the next challenge quickly follows, and that is figuring out how to make it practical." 

One notable example is The Human Genome Project. Sequencing the first human genome required years of effort and billions of dollars in investment. Today, genome sequencing can be performed in a fraction of the time and at a fraction of the cost. The underlying science is no less extraordinary, but the industry's focus changed. The challenge shifted from proving that sequencing was possible to making it scalable and accessible, and, ultimately, useful across research and medicine. In many ways, the achievement wasn't in sequencing a genome, but was in creating a pathway for sequencing to become routine.

Maxey believes a similar progression often occurs throughout biotechnology.

"The technologies that ultimately create the greatest impact aren't always the ones that prove something first," he explains. "They're often the ones that figure out how to bring those capabilities to more people."

 And that, increasingly, may be where the conversation around cell therapy is heading.

"Imagine cell engineering like a workplace conversation. If you want to deliver instructions to a remote employee, can you do that by email instead of flying him to corporate headquarters for a 2-day seminar? Likewise, can you deliver proliferation and targeting instructions to immune cells by injecting an LNP payload instead of using leukapheresis to physically pull the T-cells out of the patient's blood and culture them in the lab?"

To make autologous therapy accessible, manufacturing workflows must be cheap and scalable. Only a few years ago, antibody-based therapeutics were limited by the need to start an IV and have the patient sit through a long infusion. Now, a 150mg dose of advanced biologics can be loaded into a syringe that the patient self-injects in 20 seconds at home. This is, undoubtedly, an engineering and application improvement.

The amount of innovation happening around manufacturing is impressive. "We're seeing researchers and companies work incredibly hard to make advanced therapies more efficient and more accessible," Maxey remarks.

As In Vivo Approaches are Drawing Attention, the Delivery Layer is Becoming More Strategic

This may be part of the driving force behind the growing interest in in vivo approaches to advanced therapies. The appeal is not necessarily in completely replacing ex vivo strategies, nor is it an indication that current cell therapy models have reached their limits. But they do offer an opportunity to explore a different set of assumptions.

"I don't think this is a story about one approach winning and another losing," Maxey stresses. "It's really about expanding the toolkit. Researchers are asking whether some therapeutic objectives can be achieved through approaches that change where and how the therapy is delivered."

As interest in in vivo approaches has increased, delivery technologies are receiving significantly more attention. For years, delivery has been viewed primarily as an enabling technology. It was seen as important, sure, but it wasn't the center of the conversation. Today, that's beginning to change as researchers explore new treatment models and increasingly focus on questions surrounding tissue targeting, biodistribution, repeat dosing, safety, and therapeutic performance.

"The therapeutic objective may still reside in the payload, but increasingly, researchers are recognizing that delivery helps determine what's possible," Maxey points out.

That shift helps explain growing interest in technologies that include molecular targeting signatures incorporated into the LNP capsule.

The rapid deployment of mRNA vaccines ultimately accelerated the development of critical infrastructure like specialized manufacturing expertise, analytical capabilities, and supply chain infrastructure that can now support broader expansion of other nucleic acid therapeutics and approaches, including (but not limited to) in vivo cell therapies.

That doesn't mean delivery challenges have been solved. But it does suggest that delivery, including LNP-based approaches, is evolving from an enabling technology into a more strategic consideration when it comes to the development of next-generation therapeutics.